EyePoint (EYPT) Capital Expenditures Growth (3y) (2013 - 2026)
EyePoint (EYPT) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 16.27% |
| 10 | EyePoint | 1.08 Mn | -221.47 Mn | 168,000.00 | -41.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.08% |
| Dec 31, 2025 | 76.09% |
| Sep 30, 2025 | -72.84% |
| Jun 30, 2025 | -56.45% |
| Mar 31, 2025 | -33.41% |
| Sep 30, 2024 | 156.16% |
| Jun 30, 2024 | -144.41% |
| Jun 30, 2023 | -174.20% |
| Mar 31, 2023 | 211.58% |
| Dec 31, 2022 | 360.26% |
| Jun 30, 2022 | 105.83% |
| Mar 31, 2022 | -6.45% |
| Sep 30, 2021 | -5.04% |
| Jun 30, 2021 | -17.17% |
| Dec 31, 2020 | 60.79% |
| Sep 30, 2020 | 25.99% |
| Jun 30, 2020 | -40.91% |
| Mar 31, 2020 | 0.00% |
| Dec 31, 2019 | 6.27% |
| Jun 30, 2019 | -39.52% |